Siebring-van et al. identified that silencing SF3A3 yielded much stronger cytotoxicity to non-small cell lung cancer cells than to lung fibroblasts, suggesting that the gene could represent useful therapeutic targets [34]. This evidence concerns the gene SF3A3 and non-small cell lung carcinoma.